Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2025)

Top healthcare stocks in 2025 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Phibro Animal Health (NASDAQ:PAHC) is the #1 top healthcare stock out of 1134 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Phibro Animal Health (NASDAQ:PAHC) is: Value: A, Growth: A, Momentum: C, Sentiment: B, Safety: B, Financials: C, and AI: B.

Phibro Animal Health (NASDAQ:PAHC) has a Due Diligence Score of 42, which is 16 points higher than the healthcare sector average of 26. It passed 15 out of 38 due diligence checks and has strong fundamentals. Phibro Animal Health has seen its stock return 35.84% over the past year, overperforming other healthcare stocks by 91 percentage points.

Phibro Animal Health has an average 1 year price target of $21.50, a downside of -12.6% from Phibro Animal Health's current stock price of $24.60.

Phibro Animal Health stock has a consensus Sell recommendation according to Wall Street analysts. Of the 2 analysts covering Phibro Animal Health, 0% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a Hold, while 0% have issued a Sell rating, and 50% have issued a Strong Sell.

Ptc Therapeutics (NASDAQ:PTCT) is the #2 top healthcare stock out of 1134 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Ptc Therapeutics (NASDAQ:PTCT) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Ptc Therapeutics (NASDAQ:PTCT) has a Due Diligence Score of 38, which is 12 points higher than the healthcare sector average of 26. It passed 12 out of 33 due diligence checks and has average fundamentals. Ptc Therapeutics has seen its stock return 46.34% over the past year, overperforming other healthcare stocks by 101 percentage points.

Ptc Therapeutics has an average 1 year price target of $61.85, an upside of 33.32% from Ptc Therapeutics's current stock price of $46.39.

Ptc Therapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Ptc Therapeutics, 46.15% have issued a Strong Buy rating, 15.38% have issued a Buy, 23.08% have issued a Hold, while 0% have issued a Sell rating, and 15.38% have issued a Strong Sell.

Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #3 top healthcare stock out of 1134 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 61, which is 35 points higher than the healthcare sector average of 26. It passed 20 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 55.78% over the past year, overperforming other healthcare stocks by 111 percentage points.

Out of 72 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Jade Biosciences (NASDAQ:JBIO) has an annual dividend yield of 27.87%, which is 25 percentage points higher than the healthcare sector average of 2.46%.

Jade Biosciences's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Select Medical Holdings (NYSE:SEM) has an annual dividend yield of 13.02%, which is 11 percentage points higher than the healthcare sector average of 2.46%. Select Medical Holdings's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Select Medical Holdings's dividend has not shown consistent growth over the last 10 years.

Select Medical Holdings's dividend payout ratio of 32.4% indicates that its high dividend yield is sustainable for the long-term.

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 10.1%, which is 8 percentage points higher than the healthcare sector average of 2.46%.

Siga Technologies's dividend payout ratio of 88.2% indicates that its high dividend yield is sustainable for the long-term.

Healthcare stocks were down -1.92% in the last day, and up 1.88% over the last week. Affimed Nv was the among the top losers in the healthcare sector, dropping -80.66% yesterday.

AFMD stock has given up its prior loss. Affimed shares were trading lower after the company announced it received a Nasdaq delisting notice. Also, Wells Fargo downgraded the stock from Overweight to Equal-Weight and cut its price target from $11 to $0.1.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 55 points higher than the healthcare sector average of 16. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 13.73% in the past year. It has overperformed other stocks in the healthcare sector by 69 percentage points.

Puma Biotechnology (NASDAQ:PBYI) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 27 points higher than the healthcare sector average of 16. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has dropped -41.38% in the past year. It has overperformed other stocks in the healthcare sector by 14 percentage points.

Merck & Co (NYSE:MRK) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Merck & Co has a valuation score of 57, which is 41 points higher than the healthcare sector average of 16. It passed 4 out of 7 valuation due diligence checks.

Merck & Co's stock has dropped -40.73% in the past year. It has overperformed other stocks in the healthcare sector by 14 percentage points.

52.31% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 52.83% over the next year.

4.85% of healthcare stocks have a Zen Rating of A (Strong Buy), 11.15% of healthcare stocks are rated B (Buy), 44.61% are rated C (Hold), 26.18% are rated D (Sell), and 13.21% are rated F (Strong Sell).